跳至主要内容
临床试验/NCT04610827
NCT04610827终止4 期

Optimum Frequency and Timing of Oral Iron Administration for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder

Mayo Clinic1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2020年11月16日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
终止
发起方
Mayo Clinic
入组人数
6
试验地点
1
主要终点
Ferritin Level

研究概览

简要总结

The purpose of this research study is to see if the level of serum ferritin differs based on how often oral iron (in the form of ferrous sulfate) is given to children with restless leg syndrome/periodic limb movement disorder.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
2 Years 至 10 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Ferritin equal to or lower than 24 mcg/L drawn within the last 30 days.
  • Age 2 to 10 years.
  • Diagnosis of restless leg syndrome, periodic limb movement disorder, or sleep disturbance.

排除标准

  • Currently taking oral formulation of iron other than a multivitamin.
  • Untreated obstructive sleep apnea.
  • Gastrointestinal disorder, including gastroesophageal reflux disease and celiac disease.
  • Prior gastrointestinal surgery; e.g., gastrectomy, duodenal bypass, and presence of G-tube.
  • Use of H2 blocker, antacid, or proton pump inhibitor.
  • Inflammatory disorders, including juvenile idiopathic arthritis or inflammatory bowel disease.
  • Elevated CRP at time of initial ferritin or report of illness in past 4 weeks.

研究组 & 干预措施

Ferrous sulfate daily

Active Comparator

Subject will take 3 mg/kg oral iron in the morning

干预措施: Ferrous sulfate (Drug)

Ferrous sulfate twice daily

Active Comparator

Subjects will take 1.5 mg/kg oral iron twice daily

干预措施: Ferrous sulfate (Drug)

Ferrous sulfate every other day

Active Comparator

6 mg/kg oral iron every other day in the morning

干预措施: Ferrous sulfate (Drug)

结局指标

主要结局

Ferritin Level

时间窗: 2 months

Ferritin level in blood measured in micrograms per liter

Side Effects

时间窗: 2 months

Number of subjects to experience side effects effects (e.g., stool color change, nausea, constipation, teeth staining)

次要结局

未报告次要终点

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Julie M. Baughn

Principal Investigator

Mayo Clinic

研究点 (1)

Loading locations...

相似试验